The role of latency reversal agents in the cure of HIV: A review of current data
- PMID: 29427743
- DOI: 10.1016/j.imlet.2018.02.004
The role of latency reversal agents in the cure of HIV: A review of current data
Abstract
The definitive cure for human immunodeficiency virus type-1 (HIV) infection is represented by the eradication of the virus from the patient's body. To reach this result, cells that are infected but do not produce the virus must become recognizable to be killed by the immune system. For this purpose, drugs defined "latency reverting agents" (LRA) that reactivate viral production are under investigation. A few clinical studies have been performed in HIV-infected patients treated with LRA and combined antiretroviral therapy (cART). The strategy is thus to combine cART and LRA to reactivate the virus and unmask latently infected cells that, because of cART, cannot produce a fully competent form of the virus. Unmasked cells can present viral antigens to the immune system, that ultimately recognizes and kills such latently infected cells. This review reports and discusses recent studies that have been published on this topic.
Keywords: HDAC inhibitor; HIV; Latency; Resting CD4+ T Cells.
Copyright © 2018 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4+ T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.J Virol. 2018 Apr 13;92(9):e01931-17. doi: 10.1128/JVI.01931-17. Print 2018 May 1. J Virol. 2018. PMID: 29444937 Free PMC article.
-
Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.J Virol. 2016 Oct 14;90(21):9712-9724. doi: 10.1128/JVI.00852-16. Print 2016 Nov 1. J Virol. 2016. PMID: 27535056 Free PMC article.
-
Barriers to HIV Cure.HLA. 2016 Oct;88(4):155-63. doi: 10.1111/tan.12867. HLA. 2016. PMID: 27620852 Review.
-
In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.J Virol. 2015 Dec 9;90(4):1858-71. doi: 10.1128/JVI.02359-15. Print 2016 Feb 15. J Virol. 2015. PMID: 26656693 Free PMC article.
-
The development of immune-modulating compounds to disrupt HIV latency.Cytokine Growth Factor Rev. 2012 Aug-Oct;23(4-5):159-72. doi: 10.1016/j.cytogfr.2012.05.003. Epub 2012 Jul 4. Cytokine Growth Factor Rev. 2012. PMID: 22766356 Review.
Cited by
-
The role of integration and clonal expansion in HIV infection: live long and prosper.Retrovirology. 2018 Oct 23;15(1):71. doi: 10.1186/s12977-018-0448-8. Retrovirology. 2018. PMID: 30352600 Free PMC article. Review.
-
Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption.Viruses. 2021 Feb 21;13(2):335. doi: 10.3390/v13020335. Viruses. 2021. PMID: 33670027 Free PMC article. Review.
-
HIV chromatin is a preferred target for drugs that bind in the DNA minor groove.PLoS One. 2019 Dec 30;14(12):e0216515. doi: 10.1371/journal.pone.0216515. eCollection 2019. PLoS One. 2019. PMID: 31887110 Free PMC article.
-
Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions.Front Bioeng Biotechnol. 2022 Jun 22;10:797440. doi: 10.3389/fbioe.2022.797440. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35814023 Free PMC article. Review.
-
Therapeutic prediction of HIV-1 DNA decay: a multicenter longitudinal cohort study.BMC Infect Dis. 2021 Jun 22;21(1):592. doi: 10.1186/s12879-021-06267-5. BMC Infect Dis. 2021. PMID: 34157979 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
